Heat shock protein-based vaccines and immunotherapies

Details Heat shock protein-based vaccines and immunotherapies Heat shock protein-based vaccines and immunotherapies

2002-06-13

2009-11-17

Campell, Bruce (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Conjugate or complex

C424S196110, C424S277100, C424S278100, C530S300000

Reexamination Certificate

active

07618637

ABSTRACT:
The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious eases and cancers.

REFERENCES:
patent: 5149529 (1992-09-01), Ho et al.
patent: 5348945 (1994-09-01), Berberian et al.
patent: 5498538 (1996-03-01), Kay et al.
patent: 5541109 (1996-07-01), Searfoss
patent: 5679352 (1997-10-01), Chong et al.
patent: 5750119 (1998-05-01), Srivastava
patent: 5837251 (1998-11-01), Srivastava
patent: 5935576 (1999-08-01), Srivastava
patent: 5961979 (1999-10-01), Srivastava
patent: 5962262 (1999-10-01), Hillman et al.
patent: 5985270 (1999-11-01), Srivastava
patent: 5997873 (1999-12-01), Srivastava
patent: 6017540 (2000-01-01), Srivastava et al.
patent: 6030618 (2000-02-01), Srivastava
patent: 6048530 (2000-04-01), Srivastava
patent: 6127393 (2000-10-01), Fernandex-Pol
patent: 6331299 (2001-12-01), Rothman et al.
patent: 6641812 (2003-11-01), Rothman et al.
patent: 6656679 (2003-12-01), Rothman et al.
patent: 6663868 (2003-12-01), Rothman et al.
patent: 6673348 (2004-01-01), Rothman et al.
patent: 6719974 (2004-04-01), Rothman et al.
patent: 6761892 (2004-07-01), Rothman et al.
patent: 6773707 (2004-08-01), Rothman et al.
patent: 7309491 (2007-12-01), Slusarewicz et al.
patent: 7420037 (2008-09-01), Slusarewicz et al.
patent: 2003/0185842 (2003-10-01), Rothman et al.
patent: 2003/0185843 (2003-10-01), Rothman et al.
patent: 2004/0043419 (2004-03-01), Rothman et al.
patent: 2004/0071720 (2004-04-01), Rothman et al.
patent: 2004/0071721 (2004-04-01), Rothman et al.
patent: 2004/0071722 (2004-04-01), Rothman et al.
patent: 2004/0071723 (2004-04-01), Rothman et al.
patent: 2004/0071724 (2004-04-01), Rothman et al.
patent: 2004/0071725 (2004-04-01), Rothman et al.
patent: 2004/0101532 (2004-05-01), Houghton et al.
patent: 2004/0127684 (2004-07-01), Rothman et al.
patent: 2005/0202033 (2005-09-01), Flechtner et al.
patent: 0 538 952 (1993-04-01), None
patent: WO 89/04871 (1989-06-01), None
patent: WO 93/03766 (1993-03-01), None
patent: WO 93/17712 (1993-09-01), None
patent: WO 94/11513 (1994-05-01), None
patent: WO 94/29459 (1994-12-01), None
patent: WO 95/24923 (1995-09-01), None
patent: WO 96/10411 (1996-04-01), None
patent: WO 97/06281 (1997-02-01), None
patent: WO 97/06685 (1997-02-01), None
patent: WO 97/06821 (1997-02-01), None
patent: WO 97/10000 (1997-03-01), None
patent: WO 97/10001 (1997-03-01), None
patent: WO 97/10002 (1997-03-01), None
patent: WO 97/26910 (1997-07-01), None
patent: WO 98/23735 (1998-06-01), None
patent: WO 98/35705 (1998-08-01), None
patent: WO 99/22761 (1999-05-01), None
patent: WO 99/42121 (1999-08-01), None
Blond-Elguindi et al. Affinity Panning of a Library of Peptides Displayed on Bacteriophages Reveals the Binding Specificity of BiP. (1993) Cell, vol. 75, 717-728.
Banks et al. Recognition by a nd in Vitro Induction of Cytotoxic T Lymphocytes against Predicted Epitopes of the Immediate Early Protein ICP27 of Herpes Simplex Virus. (1993) Journal of Virology, vol. 67, 613-616.
Tavaria et al. A hitchiker's guide to the human Hsp70 family. (1996) vol. 1, 23-28.
Blond-Elguindi et al. (Cell, 1993, vol. 75, p. 717-728).
Auger et al. (Nature Medicine, 1996, vol. 2, p. 306-310).
Anderson, “Human gene therapy”, Nature 392(6679 Suppl):25-30 (1998).
Blachere et al., “Heat shock protein vaccines against cancer”, J. Immunother. 14(4):352-356 (1993).
Castelli et al., “Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells”, Cancer Res. 61(1):222-227 (2001).
Chen et al., “Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene”, Cancer Res. 60(4):1035-1042 (2000).
Fedoseyeva et al., “CD4+ T cell responses to self- and mutated p53 determinants during tumorigenesis in mice”, J. Immunol. 164(11):5641-5651 (2001).
Flajnik et al., Which came first, MHC Class I or Class II?, Immunogenetics 33:295-300 (1991).
Heike et al., “Heat shock protein-peptide complexes for use in vaccines”, J. Leukoc. Biol. 60(2):153-158 (1996).
Heikema et al., “Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides”, Immunol. Lett. 57(1-3):69-74 (1997).
Hinds et al., “Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines”, Mol Cell Biol. 7(8):2863-2869 (1987).
Huang et al., “In Vivo Cytotoxic T Lymphocytes Elicitation by Mycobacterial Heat Shock Protein 70 Fusion Proteins Maps to a Discrete Domain and Is CD4.sup.30 T Cell Independent”, J. Exp. Med. 191:403-408 (2000).
Konen-Waisman et al., “Self heat-shock protein (hsp60) peptide serves in a conjugate vaccine against a lethal pneumococcal infection”, J. Infect. Dis. 179(2):403-413 (1999).
Lewis et al., “Pilot study of vaccination with autologous tumor-derived gp96 heat shock protein-peptide complex(HSPPC-96) in patients with resected pancreatic adenocarcinoma”, Meeting Abstract, Proceedings of the Annual Meeting of the American Society of Clinical Oncology, 18:A1687 (1999).
Lopez-Guerrero et al., “Modulation of adjuvant arthritis in Lewis rats by recombinant vaccinia virus expressing the human 60-kilodalton heat shock protein”, Infect. Immun. 61(10):4225-4231 (1993).
Lovett et al., Rubella virus-specific cytotoxic T-lymphocyte responses: identification of the capsid as a target of major histocompatibility complex class I-restricted lysis and definition of two epitopes, J. Virol. 67(10):5849-5858 (1993).
Melcher et al., Tumor Immonogenicity is Determined by the Mechanism of Cell Death Via Induction of Heat Shock Protein Expression, Nature Medicine 4:581-587 (1998).
Meng et al., “Tumor suppressor gene as targets for cancer therapy”, in:Gene Therapy of Cancer, Lattime and Gerson, Eds., Academic Press, Chap. 1, pp. 3-20 (1999).
Ngo et al., “Computational Complexity Protein Structure Prediction and the Levinthal Paradox”, Birkhauser Boston, vol. 14, pp. 491-495 (1994).
Nilsson et al., “Fusion proteins in biotechnology and structural biology”, Curr. Opin. Struct. Biol. 2:569-575 (1992).
Riddell et al., “T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients”, Nature Medicine 2:216-223 (1996).
Srivastava and Udono, “Heat shock protein-peptide complexes in cancer immunotherapy”, Curr. Opin. Immunol. 6(5):728-732 (1994).
Suzuki et al., “Regulating the retention of T-cell receptor alpha chain variants within the endoplasmic reticulum: Ca(2+)-dependent association with BiP”, J. Cell Biol. 114:189-205 (1991).
Theobald et al., “Targeting p53 as a general tumor antigen”, Proc. Natl. Acad. Sci. USA 92(26):11993-11997 (1995).
Thomson et al., “Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design”, Proc. Natl. Acad. Sci. USA 92(13):5845-5849 (1995).
Thomson et al., “Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes”, J. Immunol. 157(2):822-6 (1996).
Todryk et al., “Heat Shock Protein 70 Induced During Tumor Cell Killing Induces Th1 Cytokines and Targets Immature Dendritic Cell Precursors to Enhance Antigen Uptake”, J. Immunol. 163:1398-1408 (1999).
Verma et al., “Gene therapy—promises, problems and prospects”, Nature 389(6648):239-242 (1997).
Wells et al., “Hsp72-mediated Augmentation of MHC Class I Surface Expression and Endogenous Antigen Presentation”, Int. Immunol 10:609-617 (1998).
Yamazaki et al., “Cutting Edge: Tumor Secreted Heat Shock-Fusion Protein Elicits CD8 Cells for Rejection”, J. Immunol. 16

Affiliated with

Also associated with

Rating

Heat shock protein-based vaccines and immunotherapies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heat shock protein-based vaccines and immunotherapies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heat shock protein-based vaccines and immunotherapies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4072458